Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review

被引：15

作者：

Orita, Akihiro ^{[1
]}

Hoshina, Daichi ^{[1
]}

Hirosaki, Kuninori ^{[2
]}

机构：

[1] Otaru Gen Hosp, Dept Dermatol, Otaru, Hokkaido, Japan

[2] Hokkaido Med Ctr, Dept Dermatol, Sapporo, Hokkaido, Japan

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2022年 / 47卷 / 07期

关键词：

D O I：

10.1111/ced.15183

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We report a case of pyoderma gangrenosum (PG) caused by secukinumab, which was successfully treated with risankizumab. We also reviewed reported cases of PG caused by interleukin (IL)-17 inhibitors. The clinical course of this case indicates that IL-23 may play an important role in the pathogenesis of PG and therefore IL-23-targeting therapies may be a treatment option for PG.

引用

页码：1372 / 1374

页数：3

共 5 条

[1] Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab [J].

Guenova, Emmanuella ;

Teske, Anna ;

Fehrenbacher, Birgit ;

Hoerber, Sebastian ;

Adamczyk, Annette ;

Schaller, Martin ;

Hoetzenecker, Wolfram ;

Biedermann, Tilo .

ARCHIVES OF DERMATOLOGY, 2011, 147 (10) :1203-1205

[2] Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab [J].

Jin, Kayo ;

Matsuzaki, Yasushi ;

Akasaka, Eijiro ;

Nakano, Hajime ;

Sawamura, Daisuke .

JOURNAL OF DERMATOLOGY, 2019, 46 (03) :E108-E109

[3]

Marasca Claudio, 2019, JAAD Case Rep, V5, P184, DOI 10.1016/j.jdcr.2018.12.002

[4]

Petty Amy J, 2020, JAAD Case Rep, V6, P731, DOI 10.1016/j.jdcr.2020.06.011

[5] Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction [J].

Wollina, Uwe ;

Schoenlebe, Jacqueline ;

Fuerll, Caroline .

DERMATOLOGIC THERAPY, 2020, 33 (01)

← 1 →